The main aim of this proposal is to seek safer alternatives to methadone from among the class of ligands identified in the present phase which in antinociceptive tests have full mu agonist efficacy and high potency but apparently bind irreversibly to opioid receptors and become morphine antagonists when the long lasting agonist effects have waned. Four identified candidates will be resynthesized and evaluated in binding in vitro and in vivo assays by collaborators at the University of Michigan and at the Medical College of Virginia. Further exploration of this class will involve synthesis of analogs of the 3-hydroxymorphinan derivative BU72 involving substitution of the phenyl ring, investigation of stereoselectivity, replacement of the pyrolidine bridge by tetrahydrofuran and the phenyl group by branched alkyl. It is also proposed to prepare morphinan and epoxymorphinan derivatives having similarly located aromatic rings with respect to ring A and the piperidine N-atom. It is proposed to evaluate opioids having kappa-agonist and opioid-antagonist actions as potential treatments for cocaine abuse by their effects in suppressing the behavioral sensitizing effects of cocaine. The target molecules will be N-CBM analogs of naltrindole with basic substituents in the indole aromatic ring. Selected candidates will be evaluated by Dr Toni Shippenberg of NIDA Intramural Research Division. It is proposed to have Professor Graeme Henderson, University of Bristol evaluate selected compounds from our present collection for activity at the orphan opioid receptor ORL. Should results justify it, a program of synthesis will be established.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
3R01DA007315-09S1
Application #
6323713
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Kline, Richard
Project Start
1991-08-01
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2001-06-30
Support Year
9
Fiscal Year
2000
Total Cost
$49,957
Indirect Cost
Name
University of Bristol
Department
Type
DUNS #
City
Bristol
State
Country
United Kingdom
Zip Code
BS8 1-TH
Kumar, Vinod; Polgar, Willma E; Cami-Kobeci, Gerta et al. (2018) Synthesis, Biological Evaluation, and SAR Studies of 14?-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile. Front Psychiatry 9:430
Hill, Rob; Disney, Alex; Conibear, Alex et al. (2018) The novel ?-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. Br J Pharmacol 175:2653-2661
Zieli?ska, Marta; Jarmu?, Agata; Wasilewski, Andrzej et al. (2017) Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome. Pharmacol Rep 69:350-357
Lacin, Emre; Muller, Arnaud; Fernando, Marian et al. (2016) Construction of Cell-based Neurotransmitter Fluorescent Engineered Reporters (CNiFERs) for Optical Detection of Neurotransmitters In Vivo. J Vis Exp :
Almatroudi, Abdulrahman; Husbands, Stephen M; Bailey, Christopher P et al. (2015) Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice. J Psychopharmacol 29:812-21
Hillhouse, Todd M; Porter, Joseph H (2015) A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 23:1-21
Cueva, Juan Pablo; Roche, Christopher; Ostovar, Mehrnoosh et al. (2015) C7?-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors. J Med Chem 58:4242-9
Zieli?ska, Marta; Ben Haddou, Tanila; Cami-Kobeci, Gerta et al. (2015) Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice. Eur J Pharmacol 765:582-90
Bailey, Chris P; Husbands, Stephen M (2014) Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies. Expert Opin Drug Discov 9:1333-44
Sobczak, Marta; Cami-Kobeci, Gerta; Sa?aga, Maciej et al. (2014) Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. Eur J Pharmacol 736:63-9

Showing the most recent 10 out of 22 publications